211 related articles for article (PubMed ID: 22085632)
1. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
Jean M; Alameh M; De Jesus D; Thibault M; Lavertu M; Darras V; Nelea M; Buschmann MD; Merzouki A
Eur J Pharm Sci; 2012 Jan; 45(1-2):138-49. PubMed ID: 22085632
[TBL] [Abstract][Full Text] [Related]
2. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes.
Jean M; Alameh M; Buschmann MD; Merzouki A
Gene Ther; 2011 Aug; 18(8):807-16. PubMed ID: 21412280
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
4. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
Deacon CF
Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
[TBL] [Abstract][Full Text] [Related]
5. Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for real-time RT-PCR in gene silencing.
Alameh M; Jean M; Dejesus D; Buschmann MD; Merzouki A
Int J Nanomedicine; 2010 Aug; 5():473-81. PubMed ID: 20957169
[TBL] [Abstract][Full Text] [Related]
6. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
8. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR
Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816
[TBL] [Abstract][Full Text] [Related]
9. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M
Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180
[TBL] [Abstract][Full Text] [Related]
10. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
11. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
12. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
13. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
14. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
[TBL] [Abstract][Full Text] [Related]
15. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
17. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.
Jean M; Smaoui F; Lavertu M; Méthot S; Bouhdoud L; Buschmann MD; Merzouki A
Gene Ther; 2009 Sep; 16(9):1097-110. PubMed ID: 19440230
[TBL] [Abstract][Full Text] [Related]
19. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.
Shrestha N; Araújo F; Shahbazi MA; Mäkilä E; Gomes MJ; Airavaara M; Kauppinen EI; Raula J; Salonen J; Hirvonen J; Sarmento B; Santos HA
J Control Release; 2016 Jun; 232():113-9. PubMed ID: 27091697
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylatable short peptide conjugated low molecular weight chitosan for efficient siRNA delivery and target gene silencing.
Kong F; Liu G; Sun B; Zhou S; Zuo A; Zhao R; Liang D
Int J Pharm; 2012 Jan; 422(1-2):445-53. PubMed ID: 22067703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
